{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon+response+study", "query": { "intervention": "Glucagon response study" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon+response+study&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T20:28:55.689Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06126354", "title": "Dexamethasone/Pancreatic Clamp P&F", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Prediabetic State", "Non-Alcoholic Fatty Liver Disease", "Overweight and Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Human Growth Hormone", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "OTHER" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" }, { "name": "Normal saline", "type": "OTHER" }, { "name": "Human albumin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2024-07-01", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126354" }, { "nct_id": "NCT05724134", "title": "Pancreatic Clamp in NAFLD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Prediabetic State", "Hyperinsulinemia", "Non-Alcoholic Fatty Liver Disease", "Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Growth Hormone, Human", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "OTHER" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "CORE Bar", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2023-08-29", "completion_date": "2025-09-24", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05724134" }, { "nct_id": "NCT01658501", "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "50 mg PB1023", "type": "DRUG" }, { "name": "70 mg PB1023", "type": "DRUG" }, { "name": "100 mg PB1023", "type": "DRUG" }, { "name": "Placebo (0.9% Sodium Chloride)", "type": "DRUG" }, { "name": "Victoza®", "type": "DRUG" }, { "name": "Diet and Exercise", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulfonylurea", "type": "DRUG" }, { "name": "Metformin and Sulfonylurea", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 593, "start_date": "2012-07", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 93, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658501" }, { "nct_id": "NCT05500586", "title": "The Effects of Glucagon on Hepatic Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Obesity", "Type2diabetes", "NAFLD" ], "interventions": [ { "name": "Glucagon response study", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrian Vella", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2022-10-20", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05500586" }, { "nct_id": "NCT07115069", "title": "Comparison of Body Composition Changes With Weight Loss Interventions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obesity" ], "interventions": [ { "name": "GLP-1 receptor agonist", "type": "DRUG" }, { "name": "Gastric Bypass Surgery (laparoscopic)", "type": "PROCEDURE" }, { "name": "Gastric Bypass Surgery (robotic)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2025-08-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115069" }, { "nct_id": "NCT06986603", "title": "Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypoglycemia", "Hypoglycemia, Reactive", "Bariatric Surgery" ], "interventions": [ { "name": "Glucagon for Injection (Fresenius Kabi USA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joslin Diabetes Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2024-11-26", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Boston, Massachusetts", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06986603" }, { "nct_id": "NCT06558422", "title": "Human Models of Selective Insulin Resistance: Pancreatic Clamp", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Hyperinsulinemia", "Metabolic Dysfunction Associated Steatotic Liver Disease", "Non-Alcoholic Fatty Liver Disease", "Prediabetic State", "Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Growth Hormone, Human", "type": "DRUG" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "DIAGNOSTIC_TEST" }, { "name": "[1-13C1] sodium acetate", "type": "DIAGNOSTIC_TEST" }, { "name": "Nestle BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "KIND Bar", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2027-01-01", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06558422" }, { "nct_id": "NCT01607450", "title": "Modulation of Human Myocardial Metabolism by GLP-1 Dose Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus", "Healthy" ], "interventions": [ { "name": "GLP-1 Low Dose", "type": "DRUG" }, { "name": "GLP-1 Mid-Range Dose", "type": "DRUG" }, { "name": "GLP-1 High Dose", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2010-05", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01607450" }, { "nct_id": "NCT04459338", "title": "A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Exendin-9,39", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Adrian Vella", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2021-03-04", "completion_date": "2022-06-14", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459338" }, { "nct_id": "NCT00817271", "title": "To Evaluate the Response to Glucagon During Hypoglycemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "AZD1656", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2009-02", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-05-07", "last_synced_at": "2026-09-07T20:28:55.689Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817271" } ] }